Skip to content
Screener

Glaukos GKOS Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$300M-44.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$49.2M+56.2%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$99K+57.1%
Schering-Plough logo
Schering-PloughSGP
$55K-45.0%
Bausch + Lomb logo
Bausch + LombBLCO
$2M
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$294K-93.0%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.08B+98.7%
Enterprise value$10.07B+98.2%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Other investing activities-(750)
Net cash provided by (used in) investing activities5,198(57,730)
Financing activities
Proceeds from exercise of stock options23,4319,054
Proceeds from share purchases under Employee Stock Purchase Plan2,3812,961
Payment of employee taxes related to vested restricted stock units(8,412)(7,294)
Principal paid on finance lease(640)(526)
Net cash provided by financing activities16,7604,195

Item 1. Financial Statements

FAQ

What is Glaukos's stock issuance proceeds?
Glaukos (GKOS) reported stock issuance proceeds of $4.1M in Q2 2026.
How has Glaukos's stock issuance proceeds changed year-over-year?
Glaukos's stock issuance proceeds decreased by 17.5% year-over-year, from $4.97M to $4.1M.
What is the long-term trend for Glaukos's stock issuance proceeds?
Over 4 years (2021 to 2025), Glaukos's stock issuance proceeds has grown at a -15.3% compound annual growth rate (CAGR), from $26.12M to $13.45M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Ask your AI about Glaukos's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude